 Raymond James upgraded shares of CymaBay Therapeutics NASDAQ:CBAY from an outperform rating to a strong-buy rating in a research note released on Thursday morning, The Fly reports. A number of other brokerages have also weighed in on CBAY. B. Riley reaffirmed a buy rating and set a 6.00 target price on shares of CymaBay Therapeutics ... 